ASSAY RECORD
Results
Showing up to 20 records.
| NO. | RECORD ID | NAME | SEQUENCE | SOURCE ORGANISM | FUNCTION CATEGORY | TARGET ORGANISM | ACTIVITY | ASSAY METHOD | PMID | PATENT NO | VERIFICATION STATUS |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 419241 | Rec_0431899 | Peptide P27 |
EQEEEESTGRMK |
Juglans regia [Plant] |
Antioxidant; Cytoprotective; ROS-reducing |
SH-SY5Y neuroblastoma cells |
- | H2O2-induced oxidative injury / intracellular ROS assay |
- | - |
YES |
| 419242 | Rec_0431900 | Unnamed |
LLPHHH |
synthetic construct [Synthetic] |
Antioxidant |
- |
- | ferric thiocyanate lipid-peroxidation assay |
- | - |
YES |
| 419243 | Rec_0431901 | bombesin receptor ligand peptide |
GSGQWVGHLM |
synthetic construct [Synthetic] |
Targeting; Receptor binding; Tumor targeting |
bombesin receptor on AR42-J pancreatic tumor cells |
- | competition receptor-binding assay |
- | - |
YES |
| 419244 | Rec_0431902 | Antioxidative peptide 2 |
MYPGLA |
Dasyatis kuhlii [Animal] |
Antioxidant |
- |
19.8 µM | ABTS cation radical scavenging assay (EC50) |
30236723 | - |
YES |
| 419245 | Rec_0431903 | St I 1–31 |
SELAGTIIDGASLTFEVLDKVLGELGKVSRK |
Stichodactyla helianthus [Animal] |
Hemolytic |
Human erythrocytes |
7.25±0.01 nM | HC50 |
26134716 | - |
YES |
| 419246 | Rec_0431904 | Asteropsin B |
EGCAFEGESCNVEFYPCCPGLGLTCIPGNPDGTCYYL |
Asteropus sp. [Animal] |
Proteolytic stability, Protease-resistant peptide |
chymotrypsin; elastase; pepsin; trypsin |
- | proteolytic stability assay |
24225326 | - |
YES |
| 419247 | Rec_0431905 | Asteropsin B |
EGCAFEGESCNVEFYPCCPGLGLTCIPGNPDGTCYYL |
Asteropus sp. [Animal] |
Non-cytotoxic in tested human tumor cell lines |
A-549; SK-OV-3; SK-MEL-2; XF-498; HCT-15 human tumor cell lines |
- | cytotoxicity assay (no cytotoxicity reported up to 30 μg/mL) |
24225326 | - |
YES |
| 419248 | Rec_0431906 | Alpha-mammal toxin Ts3 |
KKDGYPVEYDNCAYICWNYDNAYCDKLCKDKKADSGYCYWVHILCYCYGLPDSEPTKTNGKCKS |
Tityus serrulatus [Animal] |
Sodium channel inhibitor, Ion channel modulator, Toxin, Venom |
Nav1.4 voltage-gated sodium channel; Xenopus oocytes |
200 nM | voltage-clamp sodium-channel gating-current assay (tested concentration) |
18663133 | - |
YES |
| 419249 | Rec_0431907 | Urocortin-2 |
VILSLDVPIGLLRILLEQARNKAARNQAATNAQILARV |
Rattus norvegicus [Animal] |
CRF2 receptor ligand, Hormone, Stress-related neuropeptide |
CRF2 receptor (rat) |
8.8 dimensionless | receptor binding (pKd) |
11416224 | - |
YES |
| 419250 | Rec_0431908 | Albiglutide |
HGEGTFTSDVSSYLEGQAAKEFIAWLVKGRHGEGTFTSDVSSYLEGQAAKEFIAWLVKGRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL |
synthetic construct [Synthetic] |
Antidiabetic, Hypoglycemic, GLP-1 receptor agonist |
patients with type 2 diabetes mellitus inadequately controlled with diet and exercise |
-0.84 % HbA1c difference vs placebo | 52-week randomized placebo-controlled clinical trial (30 mg once weekly) |
26577795 | - |
YES |
| 419251 | Rec_0431909 | Albiglutide |
HGEGTFTSDVSSYLEGQAAKEFIAWLVKGRHGEGTFTSDVSSYLEGQAAKEFIAWLVKGRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL |
synthetic construct [Synthetic] |
Antidiabetic, Hypoglycemic, GLP-1 receptor agonist |
patients with type 2 diabetes mellitus inadequately controlled with diet and exercise |
-1.04 % HbA1c difference vs placebo | 52-week randomized placebo-controlled clinical trial (50 mg once weekly) |
26577795 | - |
YES |
| 419252 | Rec_0431910 | Liraglutide |
HAEGTFTSDVSSYLEGQAAKEEFIIAWLVKGRG |
synthetic construct [Synthetic] |
Antidiabetic, Hypoglycemic, GLP-1 receptor agonist |
human GLP-1 receptor; CHO cells |
1.2 pM | cAMP GLP-1R activation assay (EC50; 0% serum albumin) |
39458639 | CA2264243 |
YES |
| 419253 | Rec_0431911 | tr AIP II S7G |
CSGLF |
synthetic construct [Synthetic] |
Agr quorum-sensing inhibitor, Anti-virulence, Cell-Cell Communication, Quorum Sensing |
Staphylococcus aureus AgrC group I |
77 nM | Agr quorum-sensing inhibition assay (IC50) |
18335939 | - |
YES |
| 419254 | Rec_0431912 | tr AIP II S7G |
CSGLF |
synthetic construct [Synthetic] |
Agr quorum-sensing inhibitor, Anti-virulence, Cell-Cell Communication, Quorum Sensing |
Staphylococcus aureus AgrC group II |
238 nM | Agr quorum-sensing inhibition assay (IC50) |
18335939 | - |
YES |
| 419255 | Rec_0431913 | Cherimolacyclopeptide G |
PGAVPIYA |
synthetic construct [Synthetic] |
Antimicrobial, Antibacterial, Antifungal, Anthelmintic, Cytotoxic |
Candida albicans; Pseudomonas aeruginosa; Megascoplex konkanensis; Pontoscotex corethruses; Eudrilus spp.; Dalton's lymphoma ascites (DLA) cells; Ehrlich's ascites carcinoma (EAC) cells |
- | Qualitative functional evidence |
- | - |
YES |
| 419256 | Rec_0431914 | F2-B |
VAITLTMK |
Sorghum bicolor [Plant] |
Antioxidant |
free-radical antioxidant assay system |
74.19 % | in vitro antioxidant activity assay (DPPH/ABTS/Fe2+ chelation/reducing power) |
- | - |
YES |
| 419257 | Rec_0431915 | HR 1-11 E-G |
HGSRSGQSSGGGRHGSSSGSSSH |
synthetic construct [Synthetic] |
Antimicrobial, Antibacterial |
Pseudomonas aeruginosa ATCC 10145 |
>300 μg/mL | MBC100 |
- | US 2020/0115426 A1 |
YES |
| 419258 | Rec_0431916 | HRNR 2422-2450 |
GRHGSGSGQSSSYSPYGSGSGWSSSRGPY |
synthetic construct [Synthetic] |
Antimicrobial, Antibacterial, Bactericidal |
Pseudomonas aeruginosa ATCC 10145 |
>300 μg/mL | LD100 |
30833614 | US 2020/0115426 A1 |
YES |
| 419259 | Rec_0431917 | LambdaSo SAR endolysin RSo (SO_2973) |
MRNKVLVTGLSLSAAALITLVSSEGFSPVAEIPVKGDRPTLGFGSTYHADGRPVKLGETTTPINALKTAKAHIDKDEQRFRASLPNVELNQASYDLYIDWTYQYGIGRWLASPMRGHLIQGEYQQSCDALLLPEYRTVAGYDCSTPGNKRCYGVWLRAQQRHRDCLDALN |
LambdaSo prophage [Virus] |
Antimicrobial; Bacteriolytic; SAR endolysin; Phage-induced host-cell lysis |
Shewanella oneidensis MR-1 |
- | gene deletion/complementation; microscopy; plaque/lysis profiling; bulk-culture OD lysis assay |
38771038 | - |
YES |
| 419260 | Rec_0431918 | Cotteslosin A |
PVVXY |
Aspergillus versicolor [Fungus] |
Anticancer; Cytotoxic |
DU145 human prostate cancer cells |
141.73 μM | EC50 cytotoxicity assay |
19245260 | - |
YES |